Author + information
- Ramez S. Nairooz,
- Marwan Saad and
- Partha Sardar
Background: Long term clinical outcomes with ABSORB bioresorbable vascular scaffold (BVS) compared to second generation DES are scarce.
Methods: We searched online databases until September 2016 for studies comparing BVS vs second generation DES. We performed a meta-analysis of studies reporting follow up of 18 month or more. Random effects model odds ratio (OR) was calculated for outcomes of interest. Device-oriented composite events (DOCE) was defined as composite of cardiac mortality, target vessel myocardial infarction [TV-MI], and ischemia-driven target lesion revascularization [TLR]).
Results: A total of 2182 patients in 5 studies were included. PCI was done for stable angina or silent ischemia in 33.6%, more in the BVS group compared to the DES (40% vs 25%, p<0.001). STEMI patients were 49%, significantly less with BVS vs DES (44%, vs 56%, p<0.001). Balloon pre-dilatation was performed in 88% of BVS compared with 58% of DES (p<0.001), while balloon post-dilatation was performed in 58% of BVS compared with 39% of DES group (p<0.001). At mean follow up of 23 ± 2.1 months, BVS was associated with increased risk of DOCE (OR= 1.87; 95% CI 1.27-2.75; p=0.001) (figure), TV-MI, and definite stent thrombosis compared to DES. No differences in all-cause mortality and TLR were observed between both groups.
Conclusions: Long term outcomes with BVS need close examination especially in ACS. Randomized clinical trials are encouraged to expeditiously report long term safety and efficacy outcomes of BVS.
Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Intervention: Drug Eluting Stent & Scaffolds
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1240-131
- 2017 American College of Cardiology Foundation